Clinical Trial Update: Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update reporting multiple-dose tolerability and pharmacokinetics of IBI362 in Chinese patients with type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• IBI362

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Type 2 Diabetes | Phase 1, Phase 2 | Status: COMPLETED